Lineage Cell Therapeutics (LCTX) Notes Payables (2015 - 2019)

Lineage Cell Therapeutics' Notes Payables history runs 5 years deep, the most recent figure standing at $18000.0 for Q1 2019.

• In Q1 2019, Notes Payables fell 85.0% year-over-year to $18000.0; the TTM figure through Mar 2019 stood at $18000.0 (down 85.0% YoY), while the FY2018 annual figure was $70000.0, down 53.95% from the prior year.
• Notes Payables for Q1 2019 stood at $18000.0, down from $70000.0 in the prior quarter.
• The five-year high for Notes Payables was $2.6 million in Q2 2017, with the low at $18000.0 in Q1 2019.
• The 5-year median for Notes Payables is $97000.0 (2015), against an average of $260437.5.
• The sharpest annual moves came in 2017 and 2018: Notes Payables soared 2589.47% in 2017, then plunged 95.3% in 2018.
• Lineage Cell Therapeutics' Notes Payables stood at $95000.0 in 2015, then gained by 4.21% to $99000.0 in 2016, then soared by 53.54% to $152000.0 in 2017, then slumped by 53.95% to $70000.0 in 2018, then sank by 74.29% to $18000.0 in 2019.
• Business Quant data shows LCTX's Notes Payables at $18000.0 in Q1 2019, $70000.0 in Q4 2018, and $70000.0 in Q3 2018.